Enhancing vaccine effectiveness with delivery technology

Current Opinion in Biotechnology

Volumn 42, Issue , 2016, Pages 24-29

  Beitelshees, Marie ^a   Li, Yi ^a   Pfeifer, Blaine A ^a  

^a State University of New York   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS;

DELIVERY METHODS; DISEASE PREVENTION; IMMUNE RESPONSE;

VACCINES;

ADJUVANT; ALUMINUM HYDROXIDE; ANTIGEN; BACTERIAL VECTOR; CANCER VACCINE; DENGUE VACCINE; DNA VACCINE; EPITOPE; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; ISCOM; LIPOSOME; LIVE VACCINE; POLYELECTROLYTE; RECOMBINANT PROTEIN; SUBUNIT VACCINE; TOLL LIKE RECEPTOR 5; TOXOID; VACCINE;

CHEMOPROPHYLAXIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; IMMUNE RESPONSE; MEDICAL DEVICE; MICRONEEDLE; PRIORITY JOURNAL; REVIEW; VACCINATION; DRUG DESIGN; HUMAN; IMMUNITY; IMMUNOLOGY; PROCEDURES; TREATMENT OUTCOME;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNITY; TREATMENT OUTCOME; VACCINATION; VACCINES;

EID: 84959295089     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2016.02.022     Document Type: Review

References (54)

1. Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines 2008, Elsevier Saunders, Philadelphia. edn 5.
2. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., Hanifin J.M., Slifka M.K. Duration of antiviral immunity after smallpox vaccination. Nat Med 2003, 9:1131-1137.
3. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011, 131:509-517.
4. Reed S.G., Orr M.T., Fox C.B. Key roles of adjuvants in modern vaccines. Nat Med 2013, 19:1597-1608.
5. Dane E.L., Irvine D.J. Big thinking for adjuvants. Nat Biotechnol 2015, 33:1146-1148.
6. Pashine A., Valiante N.M., Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005, 11:S63-S68.
7. Storni T., Kündig T.M., Senti G., Johansen P. Immunity in response to particulate antigen-delivery systems. Adv Drug Deliv Rev 2005, 57:333-355.
8. Leo O., Cunningham A., Stern P.L. Vaccine immunology. Perspect Vaccinol 2011, 1:25-59.
9. Murphy B.R., Whitehead S.S. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011, 29:587-619.
10. Newell E.W., Davis M.M. Beyond model antigens: high-dimensional methods for the analysis of antigen-specific T cells. Nat Biotechnol 2014, 32:149-157.
11. Furman D., Davis M.M. New approaches to understanding the immune response to vaccination and infection. Vaccine 2015, 33:5271-5281.
12. Davis M.M. Flexibility for specificity. Science 2015, 347:371-372.
13. Desmet C.J., Ishii K.J. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012, 12:479-491.
14. Weiskopf D., Angelo M.A., Bangs D.J., Sidney J., Paul S., Peters B., de Silva A.D., Lindow J.C., Diehl S.A., Whitehead S., et al. The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol 2015, 89:120-128.
15. Nkolola J.P., Cheung A., Perry J.R., Carter D., Reed S., Schuitemaker H., Pau M.G., Seaman M.S., Chen B., Barouch D.H. Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer. Vaccine 2014, 32:2109-2116.
16. Coffman R.L., Sher A., Seder R.A. Vaccine adjuvants: putting innate immunity to work. Immunity 2010, 33:492-503.
17. Romagnani S. T-cell subsets (Th1 versus Th2). Ann Allergy Asthma Immunol 2000, 85:9-18. quiz 18, 21.
18. Mario M., D'Elios M.B., Della Bella C., Amedei A. T-cell response to bacterial agents. J Infect Dev Ctries 2011, 5.
19. Mills K.H.G., Ryan M., Ryan E., Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 1998, 66:594-602.
20. Huleatt J.W., Jacobs A.R., Tang J., Desai P., Kopp E.B., Huang Y., Song L., Nakaar V., Powell T.J. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007, 25:763-775.
21. Korsholm K.S., Petersen R.V., Agger E.M., Andersen P. T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology 2010, 129:75-86.
22. Fromen C.A., Robbins G.R., Shen T.W., Kai M.P., Ting J.P.Y., DeSimone J.M. Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization. Proc Natl Acad Sci U S A 2015, 112:488-493.
23. Parsa S., Pfeifer B. Engineering bacterial vectors for delivery of genes and proteins to antigen-presenting cells. Mol Pharmaceut 2007, 4:4-17.
24. Saxena M., Van T.T.H., Baird F.J., Coloe P.J., Smooker P.M. Pre-existing immunity against vaccine vectors - friend or foe?. Microbiology 2013, 159:1-11.
25. Wang S., Curtiss R. Development of Streptococcus pneumoniae vaccines using live vectors. Vaccine 2014, 2:49-88.
26. Zhang X., Kong W., Wanda S.-Y., Xin W., Alamuri P., Curtiss R. Generation of influenza virus from avian cells infected by Salmonella carrying the viral genome. PLOS ONE 2015, 10:e0119041.
27. Venkataswamy M.M., Ng T.W., Kharkwal S.S., Carreño L.J., Johnson A.J., Kunnath-Velayudhan S., Liu Z., Bittman R., Jervis P.J., Cox L.R., et al. Improving Mycobacterium bovis bacillus Calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells. PLOS ONE 2014, 9:e108383.
28. Seegers J.F.M.L. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 2002, 20:508-515.
29. Eypper E.H., Johnson P.V., Purro E.I., Hohmann E.L. Transcutaneous immunization of healthy volunteers with an attenuated Listeria monocytogenes vaccine strain and cholera toxin adjuvant. Vaccine 2013, 31. 10.1016/j.vaccine.2013.1005.1028.
30. Shahabi V., Maciag P.C., Rivera S., Wallecha A. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioeng Bugs 2010, 1:235-239.
31. Luquero F.J., Grout L., Ciglenecki I., Sakoba K., Traore B., Heile M., Diallo A.A., Itama C., Page A.-L., Quilici M.-L., et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 2014, 370:2111-2120.
32. Bermúdez-Humarán L.G., Kharrat P., Chatel J.-M., Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 2011, 10:S4.
33. Harro J.M., Peters B.M., O'May G.A., Archer N., Kerns P., Prabhakara R., Shirtliff M.E. Vaccine development in Staphylococcus aureus: taking the biofilm phenotype into consideration. FEMS Immunol Med Microbiol 2010, 59:306-323.
34. Anderson R.J., Pasetti M.F., Sztein M.B., Levine M.M., Noriega F.R. δguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. Vaccine 2000, 18:2193-2202.
35. Jones C.H., Ravikrishnan A., Chen M., Reddinger R., Kamal Ahmadi M., Rane S., Hakansson A.P., Pfeifer B.A. Hybrid biosynthetic gene therapy vector development and dual engineering capacity. Proc Natl Acad Sci U S A 2014, 111:12360-12365.
36. Yang Y., Hou J., Lin Z., Zhuo H., Chen D., Zhang X., Chen Y., Sun B. Attenuated Listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells. Cell Mol Immunol 2014, 11:184-196.
37. Stephan M.T., Moon J.J., Um S.H., Bershteyn A., Irvine D.J. Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med 2010, 16:1035-1041.
38. Mehta N.K., Moynihan K.D., Irvine D.J. Engineering new approaches to cancer vaccines. Cancer Immunol Res 2015, 3:836-843.
39. Adib-Conquy M., Scott-Algara D., Cavaillon J.-M., Souza-Fonseca-Guimaraes F. TLR-mediated activation of NK cells and their role in bacterial/viral immune responses in mammals. Immunol Cell Biol 2014, 92:256-262.
40. Pihlgren M., Silva A.B., Madani R., Giriens V., Waeckerle-Men Y., Fettelschoss A., Hickman D.T., López-Deber M.P., Ndao D.M., Vukicevic M., et al. TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. Blood 2012, 121:85-94.
41. Perrie Y., Crofts F., Devitt A., Griffiths H.R., Kastner E., Nadella V. Designing liposomal adjuvants for the next generation of vaccines. Adv Drug Deliv Rev 2015.
42. García-Vallejo J.J., Ambrosini M., Overbeek A., van Riel W.E., Bloem K., Unger W.W.J., Chiodo F., Bolscher J.G., Nazmi K., Kalay H., et al. Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells. Mol Immunol 2013, 53:387-397.
43. Chatin B., Mevel M., Devalliere J., Dallet L., Haudebourg T., Peuziat P., Colombani T., Berchel M., Lambert O., Edelman A., et al. Liposome-based formulation for intracellular delivery of functional proteins. Mol Ther Nucleic Acids 2015, 4:e244.
44. Zhao L., Seth A., Wibowo N., Zhao C.-X., Mitter N., Yu C., Middelberg A.P.J. Nanoparticle vaccines. Vaccine 2014, 32:327-337.
45. Li W., Joshi M.D., Singhania S., Ramsey K.H., Murthy A.K. Peptide vaccine: progress and challenges. Vaccine 2014, 2:515-536.
46. Oliveira F., Rowton E., Aslan H., Gomes R., Castrovinci P.A., Alvarenga P.H., Abdeladhim M., Teixeira C., Meneses C., Kleeman L.T., et al. A sand fly salivary protein vaccine shows efficacy against vector-transmitted cutaneous leishmaniasis in nonhuman primates. Sci Transl Med 2015, 7:290ra290.
47. Trimaille T., Verrier B. Micelle-based adjuvants for subunit vaccine delivery. Vaccine 2015, 3:803-813.
48. Shao S., Geng J., Ah Yi H., Gogia S., Neelamegham S., Jacobs A., Lovell J.F. Functionalization of cobalt porphyrin-phospholipid bilayers with his-tagged ligands and antigens. Nat Chem 2015, 7:438-446.
49. Botten J., Whitton J.L., Barrowman P., Sidney J., Whitmire J.K., Alexander J., Kotturi M.F., Sette A., Buchmeier M.J. A Multivalent vaccination strategy for the prevention of old world arenavirus infection in humans. J Virol 2010, 84:9947-9956.
50. Algar W.R., Prasuhn D.E., Stewart M.H., Jennings T.L., Blanco-Canosa J.B., Dawson P.E., Medintz I.L. The controlled display of biomolecules on nanoparticles: a challenge suited to bioorthogonal chemistry. Bioconj Chem 2011, 22:825-858.
51. Kim Y.C., Park J.H., Prausnitz M.R. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev 2012, 64:1547-1568.
52. Suh H., Shin J., Kim Y.C. Microneedle patches for vaccine delivery. Clin Exp Vaccine Res 2014, 3:42-49.
53. DeMuth P.C., Min Y., Huang B., Kramer J.A., Miller A.D., Barouch D.H., Hammond P.T., Irvine D.J. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater 2013, 12:367-376.
54. Wang B.-Z., Gill H.S., He C., Ou C., Wang L., Wang Y.-C., Feng H., Zhang H., Prausnitz M.R., Compans R.W. Microneedle delivery of an M2e-TLR5 ligand fusion protein to skin confers broadly cross-protective influenza immunity. J Control Release 2014, 178:1-7.